Loading

Investor Relations

Copyright West LLC. Minimum 15 minutes delayed.

Events

Menlo Announces Settlement to Conclude Finacea Foam Litigation and Announces that Partner, LEO Pharma A/S, Remedies Finacea Foam Supply Issues

BRIDGEWATER, N.J. , April 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc.  (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that its wholly-owned

Menlo Therapeutics Appoints Andrew Saik as Chief Financial Officer

BRIDGEWATER, N.J. , March 24, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, appointed Andrew Saik as Chief Financial

Menlo Therapeutics Provides a Business Update in the Context of COVID-19

BRIDGEWATER, N.J. , March 20, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today provided a business update in the